Shuyan Du
Overview
Explore the profile of Shuyan Du including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
502
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dattani A, Brady E, Kanagala P, Stoma S, Parke K, Marsh A, et al.
BMC Cardiovasc Disord
. 2024 Feb;
24(1):94.
PMID: 38326736
Background: Heart failure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF) frequently co-exist. There is a limited understanding on whether this coexistence is associated with distinct alterations in myocardial...
2.
Conaghan P, Nowak M, Du S, Luo Y, Landis J, Pachai C, et al.
Lancet Rheumatol
. 2024 Jan;
5(5):e263-e273.
PMID: 38251590
Background: Bruton's tyrosine kinase (BTK) is a promising biological target for rheumatoid arthritis treatment. This study examined safety, efficacy, and pharmacokinetics of BMS-986142, an oral, reversible BTK inhibitor. The aim...
3.
Kim J, Donnelly D, Tran T, Pena A, Shorts A, Petrone T, et al.
Mol Imaging Biol
. 2023 Dec;
26(2):301-309.
PMID: 38123744
Purpose: In cancer immunotherapy, the blockade of the interaction between programmed death-1 and its ligand (PD-1:PD-L1) has proven to be one of the most promising strategies. However, as mechanisms of...
4.
Donnelly D, Kim J, Tran T, Scola P, Tenney D, Pena A, et al.
Eur J Nucl Med Mol Imaging
. 2023 Dec;
51(4):978-990.
PMID: 38049658
Purpose: A same-day PET imaging agent capable of measuring PD-L1 status in tumors is an important tool for optimizing PD-1 and PD-L1 treatments. Herein we describe the discovery and evaluation...
5.
Abdelmalek M, Sanyal A, Nakajima A, Neuschwander-Tetri B, Goodman Z, Lawitz E, et al.
Clin Gastroenterol Hepatol
. 2023 Apr;
22(1):113-123.e9.
PMID: 37088458
Background & Aims: Pegbelfermin is a polyethylene glycol-conjugated analog of human fibroblast growth factor 21, a nonmitogenic hormone that regulates energy metabolism. This phase 2b study evaluated 48-week pegbelfermin treatment...
6.
Loomba R, Sanyal A, Nakajima A, Neuschwander-Tetri B, Goodman Z, Harrison S, et al.
Clin Gastroenterol Hepatol
. 2023 Apr;
22(1):102-112.e9.
PMID: 37088457
Background & Aims: Pegbelfermin is a polyethlene glycol-conjugated analog of human fibroblast growth factor 21, a nonmitogenic hormone that regulates energy metabolism. This phase 2b study evaluated 48-week pegbelfermin treatment...
7.
Brown E, Minnich A, Sanyal A, Loomba R, Du S, Schwarz J, et al.
JHEP Rep
. 2023 Mar;
5(4):100661.
PMID: 36866389
Background & Aims: FALCON 1 was a phase IIb study of pegbelfermin in patients with non-alcoholic steatohepatitis (NASH) and stage 3 fibrosis. This FALCON 1 analysis aimed to further assess...
8.
Zhuang Y, Wang Y, Liu C, Li S, Du S, Li G
Int J Radiat Oncol Biol Phys
. 2023 Jan;
116(4):894-905.
PMID: 36608830
Purpose: Danger signals released by ionizing radiation (IR) can theoretically stimulate immune activation in the tumor environment (TME), but IR alone is not sufficient to induce an effective immune response...
9.
Decato B, Leeming D, Sand J, Fischer A, Du S, Palmer S, et al.
Respir Res
. 2022 Mar;
23(1):61.
PMID: 35303880
Background: Idiopathic pulmonary fibrosis (IPF) is a debilitating lung disease with limited treatment options. A phase 2 trial (NCT01766817) showed that twice-daily treatment with BMS-986020, a lysophosphatidic acid receptor 1...
10.
Ma T, Li X, Zhu Y, Yu S, Liu T, Zhang X, et al.
Front Immunol
. 2022 Mar;
13:835879.
PMID: 35280997
Diabetic nephropathy (DN) is one of the main causes of end-stage renal disease (ESRD). Existing treatments cannot control the progression of diabetic nephropathy very well. In diabetic nephropathy, Many monocytes...